Type 1 Diabetes
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
The study will last about 33 weeks and may include up to 7 office visits and 9 telephone visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Pediatric participant (child or teen) must have type 1 diabetes, taking multiple daily insulin injections
Pediatric participant must be taking one of the following long acting insulins for at least the last 90 days: glargine, or detemir or degludec
Pediatric participant must be taking one of the following mealtime insulins for at least the last 90 days: lispro, or aspart or glulisine
Female participant who is having menstrual period must be on birth control if sexually active.
Pediatric participant must have a recent hemoglobin A1C value between 6.5% and 9.5%
Pediatric participant must not have had more than 1 emergency room visit or hospital stay for high or low blood sugar within the last 6 months